{"id":46645,"date":"2023-04-17T19:43:35","date_gmt":"2023-04-17T14:13:35","guid":{"rendered":"http:\/\/finservwealth.com\/mankind-pharma-ipo-to-open-on-april-25-closes-on-april-27\/"},"modified":"2023-04-17T19:43:35","modified_gmt":"2023-04-17T14:13:35","slug":"mankind-pharma-ipo-to-open-on-april-25-closes-on-april-27","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/mankind-pharma-ipo-to-open-on-april-25-closes-on-april-27\/","title":{"rendered":"Mankind Pharma IPO to open on April 25; closes on April 27"},"content":{"rendered":"<p> Mankind Pharma, India\u00e2\u20ac\u2122s fourth largest pharmaceutical company in terms of domestic sales and second largest in terms of sales volume for the financial year 2022, will open for subscription on April 25 and close on April 27. The anchor bidding will start on 24 April.<\/p><div id=\"finse-4142865107\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/ipo-news\/mankind-pharma-ipo-to-openapril-25-closesapril-27_16961431.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Mankind Pharma, India\u00e2\u20ac\u2122s fourth largest pharmaceutical company in terms of domestic sales and second largest in terms of sales volume for the financial year 2022, will open for subscription on April 25 and close on April 27. The anchor bidding will start on 24 April. Mankind Pharma, India\u00e2\u20ac\u2122s fourth largest pharmaceutical company in terms of domestic sales and second largest in terms of sales volume for the financial year 2022, will open for subscription on April 25 and close on April 27. The anchor bidding will start on 24 April.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/ipo-news\/mankind-pharma-ipo-to-openapril-25-closesapril-27_16961431.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> Mankind Pharma, India\u00e2\u20ac\u2122s fourth largest pharmaceutical company in terms of domestic sales and second largest in terms of sales volume for the financial year 2022, will open for subscription on April 25 and close on April 27. The anchor bidding will start on 24 April.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/ipo-news\/mankind-pharma-ipo-to-openapril-25-closesapril-27_16961431.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Mankind Pharma, India\u00e2\u20ac\u2122s fourth largest pharmaceutical company in terms of domestic sales and second largest in terms of sales volume for the financial year 2022, will open for subscription on April 25 and close on April 27. The anchor bidding will start on 24 April. Mankind Pharma, India\u00e2\u20ac\u2122s fourth largest pharmaceutical company in terms of domestic sales and second largest in terms of sales volume for the financial year 2022, will open for subscription on April 25 and close on April 27. The anchor bidding will start on 24 April.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/ipo-news\/mankind-pharma-ipo-to-openapril-25-closesapril-27_16961431.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> Mankind Pharma, India\u00e2\u20ac\u2122s fourth largest pharmaceutical company in terms of domestic sales and second largest in terms of sales volume for the financial year 2022, will open for subscription on April 25 and close on April 27. The anchor bidding will start on 24 April.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-46645","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2022\/200x200\/I\/IPO-2_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/46645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=46645"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/46645\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=46645"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=46645"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=46645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}